Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (86)	5/4/2004 7:51:12 PM
From: mopgcw	Respond to of 276

Illumina Extends BeadArray Technology to Address Wider Range of SNP Genotyping Projects Tuesday May 4, 4:24 pm ET New Microarray Offerings Enable Genotyping at 384 and 786 Multiplex SAN DIEGO--(BUSINESS WIRE)--May 4, 2004--Illumina, Inc. (NASDAQ: ILMN - News) announced today the immediate availability of two new universal Sentrix® arrays: one that can genotype 384 SNP loci per sample, and a second that can genotype 786 loci per sample. Configured in 96-sample Array of Arrays(TM) formats, the two Sentrix Array Matrices use Illumina's existing GoldenGate(TM) custom genotyping assay and are fully supported on the Company's BeadLab and BeadStation systems. ADVERTISEMENT The new genotyping products are designed for researchers who want to take advantage of Illumina's high-performance BeadArray(TM) technology, but whose projects require fewer SNPs per sample than the number currently utilized on the Company's standard 1536-plex array products. The Sentrix 384 and 786 Array Matrices feature universal oligo "addresses" which provide hybridization sites for DNA samples prepared using the GoldenGate assay protocol. Each bead type is represented greater than thirty times on average to help ensure high-confidence genotype calls. The GoldenGate assay employs an existing single-tube sample preparation and labeling kit along with a customer-specified set of loci-specific Oligator® oligos matched to the multiplex level of each Sentrix array. "Our SNP genotyping solutions deliver call rates, accuracy and pricing that are setting new industry standards," stated Jay Flatley, Illumina President and CEO. "We're very pleased to be able to extend these benefits to individual researchers who may have rich sample libraries but just a few hundred loci of experimental interest. These new array formats underscore our commitment to providing flexible and affordable solutions based on BeadArray technology," Flatley added, "We hope that these new offerings will have the same favorable impact on candidate gene and fine mapping studies that our 1536-plex arrays have had on large-scale association mapping." The development of new, moderate-complexity Sentrix arrays is a further example of Illumina's strategy to build a comprehensive offering of scalable, multi-application systems. At the foundation of our systems are the Sentrix Array Matrix, the Sentrix BeadChip, the BeadArray Reader and our Oligator DNA synthesis capability. The BeadStation system addresses moderate-throughput requirements and complements Illumina's production-scale BeadLab. Both systems can be scaled in multiple dimensions, providing customers the flexibility to perform SNP genotyping or gene expression experiments on the same platform, with content ranging from whole genomes to focused sets, at various levels of throughput and automation. Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- now used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to analyze the billions of data points necessary to extract valuable information that will help pave the way to personalized medicine.